Amneal Expands its Partnership with mAbxience for Denosumab Biosimilars and Expanding Oncology Portfolio
Shots:
- The companies collaborated for the development and commercialization of two denosumab biosimilars. Additionally, Amneal adds Prolia and Xgeva biosimilars to its oncology portfolio
- mAbxience will be responsible for developing and manufacturing the two biosimilars while Amneal will oversee the candidates through US regulatory approval pathways & also get an exclusive commercialization right in the US
- Denosumab is a mAb that inhibits bone reabsorption & is indicated for bone metastasis from various forms of cancer and prevention of bone pain and fractures, incl. osteoporosis-related injuries
Ref: Amneal | Image: Amneal
Related News:- HK inno.N Entered into an Exclusive License Agreement with mAbxience for Denosumab Biosimilar to Treat Bone Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
